Modelling and expression studies of two novel mutations causing factor V deficiency

Daniel Delev; Anna Pavlova; Stefan Heinz; Mathias Costa Blaise; Tamir Chandra; Bernd Poetsch; Erhard Seifried; Johannes Oldenburg

doi:10.1160/TH08-02-0106

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2008; 100(05): 766-772
DOI: 10.1160/TH08-02-0106

Blood Coagulation, Fibrinolysis and Cellular Haemostasis

Schattauer GmbH

Modelling and expression studies of two novel mutations causing factor V deficiency

Authors

Daniel Delev

¹Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany
Anna Pavlova

¹Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany
Stefan Heinz

²Institute for Transfusion Medicine and Immunohaematology, Red Cross Blood Donor Service, Baden-Wuerttemberg-Hessen, University Clinic Frankfurt, Germany
Mathias Costa Blaise

³Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, Nebraska, USA
Tamir Chandra

⁴Cancer Research UK, Cambridge Research Institute, Li Ka Shing Centre, Cambridge, UK
Bernd Poetsch

¹Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany
Erhard Seifried

²Institute for Transfusion Medicine and Immunohaematology, Red Cross Blood Donor Service, Baden-Wuerttemberg-Hessen, University Clinic Frankfurt, Germany
Johannes Oldenburg

¹Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany

Abstract

Summary

Human coagulation factor V (FV), a non-enzymatic cofactor of the prothrombinase complex, is required for the rapid generation of thrombin. FV deficiency is a rare autosomal recessive bleeding disorder. We describe two novel mutations,Tyr91Asn and Asp2098Tyr,found in two probands with a residual FV activity of 51% and 4%, respectively. Modelling and structural analysis of these mutations were performed following short-duration molecular dynamics (MD) simulation.Asp2098Tyr lead to abolishment of the highly conserved salt bridge Asp2098-Arg2171 presumably required for structural integrity of the C2 domain. MD studies suggest that additional conformational changes resulting from this mutation involve local rearrangements at Tyr2063 and Tyr2064 and so affect the phospholipid-membrane binding. MD modelling of the Try91Asn mutant revealed a conformational change nearby the Cu²⁺ binding site that could affect overall stabilization of the heavy and light chains. These findings suggest that both mutations influence the structural integrity of FV protein. Transient expression data of wild-type and mutant FV variants in 293T human embryonic kidney cells showed FV-specific activity reduced to 26% for Asp2098Tyr and 56% for Tyr91Asn compared to that of wild-type. Thus, both the data from the short duration molecular dynamic simulation and from expression analysis indicate alterations of the FV protein variants that explain the clinical phenotype.

Keywords

Factor V deficiency - novel mutations - MD simulation - transient expression studies

Full Text

References

References
1 Jenny RJ, Tracy PB, Mann KG. The physiology and biochemistry of factor V. In: Haemostasis and Thrombosis. 3rd ed. Edinburgh: Churchill Livingstone; 1994: 465-476.
2 Tuddenham EGD, Cooper DN. Factor V: The molecular genetics of haemostasis and its inherited disorders. Oxford, U. K: Oxford University Press; 1994
3 Mann KG, Kalafatis M. Factor V: a combination of Dr Jekyll and Mr Hyde. Blood 2003; 101: 20-30.
4 Kalafatis M, Egan JO, van Veer C. et al. The regulation of clotting factors. Crit Rev Eukaryot Gene Expr 1997; 07: 241-280.
5 Kane WH, Davie EW. Blood coagulation factors V and VIII: structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders. Blood 1988; 71: 539-555.
6 Macedo-Ribeiro S, Bode W, Huber R. et al. Crystal structures of the membrane-binding C2 domain of human coagulation factor V. Nature 1999; 402: 434-439.
7 Pratt KP, Shen BW, Takeshima K. et al. Structure of the C2 domain of human factor VIII at 1.5 A resolution. Nature 1999; 402: 439-442.
8 Zaitsev VN, Zaitseva I, Papiz M. et al. An X-ray crystallographic study of the binding sites of the azide inhibitor and organic substrates to ceruloplasmin, a multi-copper oxidase in the plasma. J Biol Inorg Chem 1999; 04: 579-587.
9 Adams TE, Hockin MF, Mann KG. et al. The crystal structure of activated protein Cinactivated bovine factor Va: Implications for cofactor function. Proc Natl Acad Sci USA 2004; 101: 8918-8923.
10 Spiegel Jr PC, Jacquemin M, Saint-Remy JM. et al. Structure of a factor VIII C2 domain-immunoglobulin G4kappa Fab complex: identification of an inhibitory antibody epitope on the surface of factor VIII. Blood 2001; 98: 13-19.
11 Pemberton S, Lindley P, Zaitsev V. et al. A molecular model for the triplicated A domains of human factor VIII based on the crystal structure of human ceruloplasmin. Blood 1997; 89: 2413-2421.
12 Villoutreix BO, Dahlback B. Structural investigation of the A domains of human blood coagulation factor V by molecular modeling. Protein Sci 1998; 07: 1317-1325.
13 Pellequer JL, Gale AJ, Getzoff ED. et al. Three-dimensional model of coagulation factor Va bound to activated protein C. Thromb Haemost 2000; 84: 849-857.
14 Orban T, Kalafatis M, Gogonea V. Completed three-dimensional model of human coagulation factor va. Molecular dynamics simulations and structural analyses. Biochemistry 2005; 44: 13082-13090.
15 Cripe LD, Moore KD, Kane WH. Structure of the gene for human coagulation factor V. Biochemistry 1992; 31: 3777-3785.
16 Foster WB, Nesheim ME, Mann KG. The factor Xa-catalyzed activation of factor V. J Biol Chem 1983; 258: 13970-13977.
17 Suzuki K, Dahlback B, Stenflo J. Thrombin-catalyzed activation of human coagulation factor V. J Biol Chem 1982; 257: 6556-6564.
18 Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem 1994; 269: 31869-31880.
19 Koeleman BP, Reitsma PH, Bakker E. et al. Location on the human genetic linkage map of 26 genes involved in blood coagulation. Thromb Haemost 1997; 77: 873-878.
20 Jenny RJ, Pittman DD, Toole JJ. et al. Complete cDNA and derived amino acid sequence of human factor V. Proc Natl Acad Sci USA 1987; 84: 4846-4850.
21 Lak M, Sharifian R, Peyvandi F. et al. Symptoms of inherited factor V deficiency in 35 Iranian patients. Br J Haematol 1998; 103: 1067-1069.
22 Peyvandi F, Mannucci PM. Rare coagulation disorders. Thromb Haemost 1999; 82: 1207-1214.
23 Schrijver I, Hong DW, Mandle L. et al. High frequency of premature termination mutations in the factor V gene: three factor V deficiency case reports and a mutation review. Thromb Haemost 2005; 93: 610-611.
24 Vos HL. An online database of mutations and polymorphisms in and around the coagulation factor V gene. J Thromb Haemost 2007; 05: 185-188.
25 Chen TY, Lin TM, Chen HY. et al. Gly392Cys missense mutation in the A2 domain of factor V causing severe factor V deficiency: molecular characterization by expression of the recombinant protein. Thromb Haemost 2005; 93: 614-615.
26 Asselta R, Tenchini ML, Duga S. Inherited defects of coagulation factor V: the hemorrhagic side. J Thromb Haemost 2006; 04: 26-34.
27 Montefusco MC, Duga S, Asselta R. et al. Clinical and molecular characterization of 6 patients affected by severe deficiency of coagulation factor V: Broadening of the mutational spectrum of factor V gene and in vitro analysis of the newly identified missense mutations. Blood 2003; 102: 3210-3216.
28 Cai XH, Wang XF, Ding QL. et al. Factor V C1149G and 5609-10INSCGTGGTT causing factor V deficiency: molecular characterization by in-vitro expression. Thromb Haemost 2007; 98: 683-685.
29 Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
30 Berman HM, Westbrook J, Feng Z. et al. The Protein Data Bank. Nucleic Acids Res 2000; 28: 235-242.
31 Kleywegt GJ, Jones TA. Halloween [2026] masks and bones. In: From First Map to Final Model. Warrington: SERC Daresbury Laboratory; 1994: 59-66.
32 Kleywegt GJ. Use of non-crystallographic symmetry in protein structure refinement. Acta Crystallogr D Biol Crystallogr 1996; 52: 842-857.
33 Pettersen EF, Goddard TD, Huang CC. et al. UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem 2004; 25: 1605-1612.
34 Marquette KA, Pittman DD, Kaufman RJ. The factor V B-domain provides two functions to facilitate thrombin cleavage and release of the light chain. Blood 1995; 86: 3026-3034.
35 Ortel TL, vore-Carter D, Quinn-Allen M. et al. Deletion analysis of recombinant human factor V. Evidence for a phosphatidylserine binding site in the second C-type domain. J Biol Chem 1992; 267: 4189-4198.
36 Ajzner EE, Balogh I, Szabo T. et al. Severe coagulation factor V deficiency caused by 2 novel frameshift mutations: 2952delT in exon 13 and 5493insG in exon 16 of factor 5 gene. Blood 2002; 99: 702-705.
37 van WR, Nieuwenhuis K, van den BM. et al. Five novel mutations in the gene for human blood coagulation factor V associated with type I factor V deficiency. Blood 2001; 98: 358-367.
38 Schrijver I, Houissa-Kastally R, Jones CD. et al. Novel factor V C2-domain mutation (R2074H) in two families with factor V deficiency and bleeding. Thromb Haemost 2002; 87: 294-299.
39 Bossone A, D’Angelo F, Santacroce R. et al. Factor V Arg2074Cys: a novel missense mutation in the C2 domain of factor V. Thromb Haemost 2002; 87: 923-924.
40 Duga S, Montefusco MC, Asselta R. et al. Arg2074Cys missense mutation in the C2 domain of factor V causing moderately severe factor V deficiency: molecular characterization by expression of the recombinant protein. Blood 2003; 101: 173-177.
41 Wang Z, Moult J. SNPs, protein structure, and disease. Hum Mutat 2001; 17: 263-270.
42 Marchetti G, Gemmati D, Patracchini P. et al. Direct detection of a missense mutation causing severe hemophilia A by PCR amplification and fluorescence scanning. Hematol Pathol 1990; 04: 185-188.
43 Lewis DA, Moore KD, Ortel TL. Factor VIII Arg2304 --> His binds to phosphatidylserine and is a functional cofactor in the factor X-ase complex. Thromb Haemost 2001; 85: 260-264.
44 Kim SW, Quinn-Allen MA, Camp JT. et al. Identification of functionally important amino acid residues within the C2-domain of human factor V using alaninescanning mutagenesis. Biochemistry 2000; 39: 1951-1958.